Reuters reports "a major success in a new field of cancer treatment this week, as Moderna and Merck announced a personalized mRNA cancer vaccine "reduced the risk of recurrence and spread of melanoma in a late-stage trial". The vaccine was tested with Merck's widely used immunotherapy drug Keytruda:Thousands of patients who have undergone surgery to remove high-risk melanoma tumors could benefit as soon as next year if regulators approve the vaccine, Moderna President Stephen Hoge said in an interview. This is the first positive late-stage trial result for an mRNA cancer vaccine, which trains a patient's immune system to fight tumors by targeting specific mutations in those cells, and the first such study to show that adding a treatment to Keytruda worked better than that therapy alone... Interim results of the ongoing study, released on Wednesday, found the treatment, Intismeran, met both its primary target of reducing cancer recurrence and its secondary goal of preventing tumors from spreading to other parts of the body, compared with Keytruda alone. When the vaccine is injected into a patient, the patient's cells produce copies of mutations for the immune system to recognize and destroy... Merck said the companies are already in talks with regulators about the treatment. "Merck, Moderna and other companies are testing similar approaches against lung, breast and pancreatic cancers," the article points out. It adds that Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, "said the Moderna results could signal a new era for treating solid-tumor cancers." More from CNN:The trial result is "a monumental leap forward," validating mRNA technology as a cancer treatment, said Dr. Julie Gralow, chief medical officer of the American Society of Clinical Oncology... Roche and BioNTech, whose mRNA technology was used in the Pfizer COVID vaccines, are testing a similar treatment called autogene cevumeran in mid-stage studies in colon and pancreatic cancer patients who have undergone surgery. Results of the colon cancer trial are expected in 2027, with pancreatic trial results to follow in 2031. "We should be hearing results from multiple studies over the next few years and there's every reason to hope now, with this news, that many of them will be positive," said Dr. Robert Vonderheide, director of Penn Medicine's Abramson Cancer Center and president-elect of the American Association for Cancer Research.Read more of this story at Slashdot.